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A B S T R A C T   
Spike-specific antibodies contribute significantly to the neutralising activity against SARS-CoV-2 and are 
important for the therapeutic effect of convalescent plasma. B.1.1.7 is a recently emerged variant of SARS-CoV-2 
that has several mutations in the gene encoding for the spike-protein. To assess the potential effect these mu-
tations could have on the neutralising efficacy of antibodies, we evaluated 96 serum samples from convalescent 
plasma donors collected before the first occurrence of B.1.1.7 and tested their neutralising effect on wild-type 
SARS-CoV-2 and B.1.1.7. We found that B.1.1.7 is more resistant to neutralisation by convalescent plasma 
from patients infected with wild-type SARS-CoV-2 with an overall decrease in neutralising activity of 47.7%. 
Thus, the neutralising effect of convalescent plasma should be determined against the major circulating virus 
clades whenever possible to ensure the best possible therapeutic effect.   
COVID-19 continues to threaten global health. As there are still no 
strongly effective, specific antiviral treatment options available, 
convalescent plasma is being used worldwide to treat patients suffering 
from severe COVID-19. However, the emergence and rapid spread of 
virus variants such as the variant of concern (VOC) 202,012/01, 
commonly referred to as B.1.1.7, raises the question of possible differ-
ences in neutralising ability and thus effectiveness of using convalescent 
plasma derived from donors infected with wild-type SARS-CoV-2 in 
patients infected with B.1.1.7. We evaluated 96 serum samples from 
convalescent plasma donors collected between April and May 2020 
before the first occurrence of B.1.1.7 and tested their neutralising effect 
on both wild-type SARS-CoV-2 and B.1.1.7. 
Lineage B.1.1.7 is one of several variants thought to be of particular 
importance, mainly because recent data suggest that they are signifi-
cantly more transmissible than wild type (WT) SARS-CoV-2. [1]. One of 
the key questions here is whether certain mutations could enable im-
mune evasion, including escape from neutralising antibodies (NAbs) as 
previously described in vitro [2]. amongst others, B.1.1.7 has several 
mutations in the receptor-binding domain of the spike protein [3]. 
However, it is known that spike-specific antibodies contribute 
significantly to the neutralising activity and are thus important for the 
therapeutic effect of convalescent plasma [4]. To assess the neutralising 
efficacy of NAbs in convalescent plasma from patients infected with WT 
virus on B.1.1.7, we evaluated 96 anonymised serum samples collected 
between April and May 2020. All samples were from donors who had 
recently recovered from COVID-19 and donated convalescent plasma. 
All patients had to be hospitalized and required oxygen during the 
course of the infection, none required mechanical ventilation. Samples 
were taken four weeks after complete recovery from COVID-19 ac-
cording to official guidelines of the German Federal Institute for Vac-
cines and Biomedicines [5]. All samples had a serological profile 
consistent with recent SARS-CoV-2 infection, i.e. SARS-CoV-2 specific 
IgA and/or IgG antibodies determined by a commercial ELISA (Euro-
immun, Lübeck, Germany) (data not shown). 
Micro-neutralisation test 
WT SARS-CoV-2 (strain MUC IMB-1, clade B1) and B.1.1.7 (strain 
MUC IMB-B.1.1.7) neutralising antibody (NAb) titres were determined 
as previously described [6]. Briefly, heat-inactivated serum samples 
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(duplicates), including positive and negative control samples, were 
serially diluted in 96-well tissue culture plates starting at 1:5 [7] to a 
maximum of 1:640. Virus stocks (50 TCID/50 µl) were prepared and 
stored at − 80 ◦C. Virus was pre-incubated (1 h, 37 ◦C) with diluted 
serum samples before Vero E6 cells (1 × 104 cells/50 µl) were added to 
each well. After 72 h (37 ◦C), supernatants were discarded and wells 
were fixed (3% formalin/PBS) and stained (crystal violet, 0.1%). The 
NAbs titre corresponded to the reciprocal of the highest serum dilution 
showing complete inhibition of CPE. A virus re-titration was performed 
on every plate and exact titres were determined by retrograde calcula-
tion. Overall, the mean NAbs titres were 36 for WT virus and 14 for 
B.1.1.7. 
Comparison of NAbs titres against WT and B.1.1.7 
Direct comparison of NAbs titres showed that the majority (60/76) of 
serum samples retained their ability to neutralise when tested against 
B.1.1.7. However, titres against B.1.1.7 were generally lower compared 
to titres against WT virus (Fig. 1). Overall, the ability to neutralise was 
reduced in all but four samples, where titres remained the same. A total 
of 16 serum samples showed no neutralising effect when tested against 
B.1.1.7, although they were able to further neutralise WT virus in par-
allel control tests. No change in titre was observed four samples. Addi-
tionally, all 20 samples that were initially negative for NAbs against WT 
virus also remained negative when tested against B.1.1.7. Thus, only 
four samples were able to fully retain their neutralising ability. Only one 
sample increased its neutralising ability by 20% when tested against 
B.1.1.7. The mean loss of neutralising activity against B.1.1.7 was 47.7% 
compared to WT virus, but we observed a wide range of titre changes 
(Fig. 2). The largest decrease was observed in a serum that showed an 
initial titre of 88 against WT SARS-CoV-2 but no neutralising activity 
Fig. 1. Direct comparison of NAbs titres against WT virus (orange) and B.1.1.7 (blue) shows a general trend towards a decrease in titre levels. While the 
majority of serum samples were still able to neutralise B.1.1.7, most samples show a decrease in NAbs titre levels. The greatest decrease was observed in one sample, 
which dropped from an initial titre of 80 against WT virus to no neutralising effect against B.1.1.7 (Fig. 1, red). 16 serum samples lost their neutralising effect 
completely against B.1.1.7. Only one sample showed a slight increase in neutralising efficacy when tested against B.1.1.7 (green). In total, 96 samples were tested. 
The number of samples with the same titre is shown in the respective circle. 
Fig. 2. Percentage differences in NAbs titres demonstrate an overall 
decrease in neutralising efficacy While the majority of samples showed a 
decrease in titre values, neutralising efficacy was completely abolished in 16 
samples. Four samples retained their neutralising efficacy. Additionally, all 20 
samples that were initially negative for NAbs against WT virus also remained 
negative when tested against B.1.1.7 (grey). 
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against B.1.1.7 (Fig. 1, red). Overall, the decrease in NAbs titres against 
B.1.1.7 compared to WT virus was statistically significant (p<0.0001 by 
Wilcoxon) (Fig. 2). Taken together, these results suggest that B.1.1.7 has 
the ability to escape NAbs in some, but not all, convalescent plasmas of 
early COVID-19 patients. 
Correlation of the NAbs titres 
In addition, we examined the correlation of the NAbs titres. A weak 
correlation (r = 0.86) was observed between the NAb titre against WT 
SARS-CoV-2 and the titre against B.1.1.7 of the same serum sample 
(Fig. 3). However, as the titre changes were highly variable, no pre-
dictions could be made about the neutralising activity against B.1.1.7 
based on the NAbs titre against WT virus. 
Discussion 
Neutralising antibodies are a key component of the adaptive immune 
system that can be transferred as convalescent plasma to temporarily 
induce passive immunity [8]. The extent to which genetic variations in 
SARS-CoV-2 influence the effectiveness of convalescent plasma therapy 
is currently unknown [9]. 
Our results show that SARS-CoV-2 variant B.1.1.7 is more resistant 
than WT virus to neutralisation by convalescent plasma from patients 
infected between March and May 2020, before the emergence of B.1.1.7. 
Although a certain correlation between titres could be observed, no 
reliable prediction about a possible neutralising efficacy of a serum 
against B.1.1.7 can be derived from the NAbs titre obtained against WT 
virus. 
Our findings are in contrast to the results of a recently published 
study by Planas et al., in which no significant reduction in neutralisation 
against B.1.1.7 was found [10]. On the other hand, there are several 
other studies reporting reduced neutralisation similar to our results 
[11–13]. These discrepancies might be attributed to the differences in 
virus strains serving as “wild-type” SARS-CoV-2 control viruses and 
should be investigated further. 
Whether the potentially reduced susceptibility could indicate a 
higher risk of re-infection with new variants should be investigated in 
future studies. At the same time, it is important to continuously monitor 
the effectiveness of vaccines against emerging variants, as most 
currently licensed vaccines induce antibodies against the spike protein 
or parts thereof [8,14]. 
The fact that one serum shows an increase in neutralising efficacy 
against B.1.1.7 may indicate that mutations in SARS-CoV-2 do not 
necessarily lead to limitations of the immune defence in every case. In 
individual cases, polyvalent antibody formation can apparently even 
lead to improvements in the neutralising ability against a mutation 
variant. It must be said, however, that the increase in neutralisation 
capacity observed by us was overall low in this single serum. Moreover, 
only a limited initial titre against WT virus was found. 
Conclusion 
The use of convalescent plasma in the treatment of patients with 
severe COVID-19 is undoubtedly an important tool in the fight against 
SARS-CoV-2 [15]. However, therapeutic success depends, amongst 
other things, on the quantity and specificity of NAbs. As new 
SARS-CoV-2 variants emerge, it is important to gather knowledge about 
the cross-reactivity of NAbs against different clades. Our results show 
that there is some cross-reactivity between NAbs generated against WT 
SARS-CoV-2 and B.1.1.7. Thus, the use of convalescent plasma in pa-
tients infected with B.1.1.7 may generally have a positive effect. How-
ever, we observed partly large differences in the neutralising activity. 
Therefore, the neutralising effect of convalescent plasma should be 
determined against the major circulating virus clades whenever possible 
and should be administered to patients infected with a clade that is 
efficiently neutralised by the plasma. In clinical situations where this is 
not always possible, our data suggest that convalescent plasma with high 
NAbs titres is more likely to maintain its neutralising effect albeit po-
tential clade differences. 
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Fig. 3. A low-grade correlation was observed between the titres against 
WT virus and B.1.1.7. Despite the low degree correlation observed (r = 0.86, 
Pearson regression analysis), no prediction about the neutralising efficacy of a 
serum against B.1.1.7 can be extrapolated from the NAbs titre obtained against 
WT virus. 
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